BTG Pharmaceuticals (now SERB Pharmaceuticals)

BTG Pharmaceuticals, now known as SERB Pharmaceuticals, is a leading global specialist pharmaceutical company headquartered in the UK. The company focuses on developing and commercialising innovative treatments for patients with serious conditions, particularly in the fields of oncology, critical care, and pain management.

With a commitment to improving patient outcomes, SERB Pharmaceuticals invests heavily in research and development to bring new therapies to market. The company’s portfolio includes a range of products that address unmet medical needs, ensuring that patients have access to effective treatments.

SERB Pharmaceuticals operates in over 100 countries, demonstrating its extensive reach and dedication to global health. The company collaborates with healthcare professionals, researchers, and institutions to advance medical science and enhance therapeutic options.

In addition to its focus on innovation, SERB Pharmaceuticals prioritises quality and compliance, adhering to stringent regulatory standards across all its operations. The company’s manufacturing facilities are equipped with state-of-the-art technology, ensuring the highest quality of products.

As part of its vision, SERB Pharmaceuticals aims to be a trusted partner in healthcare, providing solutions that improve the quality of life for patients worldwide. The company’s mission is driven by a passion for science and a commitment to making a difference in the lives of those it serves.

• Core Activities: Development and commercialisation of pharmaceutical products.
• Focus Areas: Oncology, critical care, and pain management.
• Global Reach: Operations in over 100 countries.
• Commitment to Quality: Adherence to regulatory standards and high-quality manufacturing.

Through its dedication to innovation and patient care, SERB Pharmaceuticals continues to lead the way in the pharmaceutical industry, striving to meet the evolving needs of healthcare.